

Brigitte Michelsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7230321/publications.pdf>

Version: 2024-02-01

23
papers

641
citations

686830

13
h-index

676716

22
g-index

23
all docs

23
docs citations

23
times ranked

917
citing authors

#	ARTICLE	IF	CITATIONS
1	Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1906-1910.	0.5	162
2	A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis. <i>PLoS ONE</i> , 2015, 10, e0123582.	1.1	94
3	Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 708-711.	0.5	45
4	Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2108-2113.	0.5	40
5	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280.	1.8	33
6	Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. <i>Arthritis Research and Therapy</i> , 2020, 22, 198.	1.6	31
7	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for Psoriatic Arthritis (DAPSA) based on 28 joints?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1736-1741.	0.5	30
8	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1410-1418.	0.5	28
9	Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1290-1294.	0.5	21
10	Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. <i>RMD Open</i> , 2020, 6, e001223.	1.8	21
11	Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. <i>RMD Open</i> , 2018, 4, e000631.	1.8	20
12	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. <i>Arthritis Care and Research</i> , 2022, 74, 1205-1218.	1.5	20
13	Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. <i>Journal of Rheumatology</i> , 2017, 44, 431-436.	1.0	18
14	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. <i>Arthritis Research and Therapy</i> , 2018, 20, 160.	1.6	16
15	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 3635-3645.	0.9	14
16	Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 12-16.	1.6	13
17	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 2455-2461.	0.9	7
18	European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. <i>Rheumatology</i> , 2022, 61, 3799-3807.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. <i>RMD Open</i> , 2020, 6, e001372.	1.8	6
20	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 4741-4751.	0.9	6
21	Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. <i>PLoS ONE</i> , 2022, 17, e0266816.	1.1	6
22	Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study. <i>Rheumatology and Therapy</i> , 2022, 9, 1171-1179.	1.1	2
23	FRI0439â€¦PERCEIVED INFLUENCE OF HEALTH STATUS ON SEXUAL ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS IS ASSOCIATED WITH MUSCULOSKELETAL MANIFESTATIONS BUT NOT WITH PSORIASIS SKIN MANIFESTATIONS. , 2019, , .		1